Brief: Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease
29/04/2025 13:26
April 29 (Reuters) - Palatin Technologies Inc PTN.A: PALATIN ANNOUNCES BREAKTHROUGH SYMPTOM RESOLUTION IN UPDATED ANALYSES FROM PHASE 3 PL9643 MELODY-1 CLINICAL TRIAL IN DRY EYE DISEASE Source text: ID:nPn753B6wa Further company coverage: PTN.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity